Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Conclusions
The comparison of RTX treated versus untreated matched-control SSc patients from the EUSTAR cohort demonstrated improvement of skin fibrosis and prevention of worsening lung fibrosis, supporting the therapeutic concept of B cell inhibition in SSc.

Source: Annals of the Rheumatic Diseases - May 8, 2015 Category: Rheumatology Authors: Jordan, S., Distler, J. H. W., Maurer, B., Huscher, D., van Laar, J. M., Allanore, Y., Distler, O., Airo, Sancho, Ananjeva, Ancuta, Aringer, Balbir-Gurman, Cantatore, Caramaschi, Chatelus, Codullo, Farge-Bancel, Foti, Gabrielli, Henes, Herrgott, Iannone, Tags: Immunology (including allergy), Interstitial lung disease, Connective tissue disease, Musculoskeletal syndromes, Epidemiology Clinical and epidemiological research Source Type: research